Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa
Por:
Zouboulis CC, Hansen H, Caposiena Caro RD, Damiani G, Delorme I, Pascual J, Reguiai Z, Trigoni A, Vilarrasa E and Alfageme Roldán F
Publicada:
1 feb 2020
Ahead of Print:
18 oct 2019
Categoría:
Dermatology
Resumen:
Background: Adalimumab is the only approved compound for the treatment of adult patients with moderate-to-severe hidradenitis suppurativa (HS) who did not respond to a systemic classical treatment. Despite its significant short- and long-term efficacy, a percentage of patients do not respond sufficiently. Moreover, some primary responders experience a response loss with time. Objective: To analyse the effectiveness of adalimumab dose intensification in HS patients. Methods: A case series of adalimumab 80 mg/week subcutaneously (s.c.) compassionate use in patients with HS, who did not respond sufficiently or in primary responders with progressive response loss to the registered adalimumab dose of 40 mg/week s.c. Patients were collected and evaluated retrospectively. Patients' data were extracted from medical records. Results: The 14 patients collected were Caucasian with HS of Hurley stage II-III and moderate or severe International HS Severity Score System (IHS4) stage. Adalimumab dose intensification significantly improved IHS4 score, Pain Index, HS-Physician Global Assessment, pain, and Cardiff Dermatology Life Quality Index. Two young female patients with HS and Crohn's disease developed psoriatic lesions during the treatment with adalimumab 80 mg/week s.c. Conclusion: An enhanced level of effectiveness was assessed in the majority of the HS patients treated with adalimumab dose intensification (80 mg/week s.c.). Larger studies are required to evaluate this observation.
Filiaciones:
Zouboulis CC:
Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane, Dessau, Germany,
European Hidradenitis Suppurativa Foundation e.V., Dessau, Germany,
Hansen H:
Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane, Dessau, Germany
Caposiena Caro RD:
European Hidradenitis Suppurativa Foundation e.V., Dessau, Germany
Department of Dermatology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
Damiani G:
European Hidradenitis Suppurativa Foundation e.V., Dessau, Germany
Clinical Dermatology, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy
Delorme I:
Dr. Isabelle Delorme Inc., Drummondville, Québec, Canada
Pascual J:
European Hidradenitis Suppurativa Foundation e.V., Dessau, Germany
Department of Dermatology, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation), Alicante, Spain
Reguiai Z:
European Hidradenitis Suppurativa Foundation e.V., Dessau, Germany
Department of Dermatology, Reims University Hospital, University of Champagne-Ardenne, Reims, France
Trigoni A:
European Hidradenitis Suppurativa Foundation e.V., Dessau, Germany
Second Department of Dermatology and Venereology, General Hospital Papageorgiou, Aristotle University of Thessaloniki, Thessaloniki, Greece
Vilarrasa E:
European Hidradenitis Suppurativa Foundation e.V., Dessau, Germany
Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain
Alfageme Roldán F:
Department of Dermatology, University Hospital Puerta De Hierro Majadahonda, Madrid, Spain
|